ODM Potency Evaluation by Seasons & Origins
Quantifying chemical divergence across harvest cycles, geographical terroirs, and anatomical tissues to lock in optimal sourcing matrices.
Discover our primary analytical, screening, and pharmacological study modules engineered for global enterprise procurement and regulatory approval.
Quantifying chemical divergence across harvest cycles, geographical terroirs, and anatomical tissues to lock in optimal sourcing matrices.
Targeted phenotypic and molecular assays isolating alkaloids, flavonoids, and saponins yielding maximum bio-efficacy and extraction yield.
Developing and validating HPTLC, HPLC-DAD, and GC-MS profiling standards compliant with USP, EP, and ChP pharmacopeial monographs.
Designing GCP-compliant clinical trials, pharmacokinetic studies, and small-cohort dietary supplement efficacy validation programs.
High-throughput cellular modeling, enzymatic pathway inhibition assays, and targeted organ-on-a-chip mechanistic evaluations.
Comprehensive acute toxicity (LD50), sub-chronic 90-day oral toxicity, safety pharmacology, and metabolic fate determinations.
End-to-end identification of high-yield molecular markers from crude plant matrices with full chemometric profile documentation.
Full qualification of agricultural provenance, geographical indications, and heavy metal/pesticide baseline elimination.
Meeting the stringent specifications of global enterprise procurement requires transforming traditional herbal wisdom into rigorous, reproducible chromatographic and clinical data.
Global procurement teams at Tier-1 pharmaceutical and nutraceutical enterprises no longer purchase generic commodity botanicals. The modern procurement mandate demands Chemistry, Manufacturing, and Controls (CMC) dossiers, batch reproducibility (RSD < 2.0%), transparent supply chains, and established audit-ready Drug Master Files (DMF) or Active Substance Master Files (ASMF).
MedGence (Yineng Pharma) bridges this technical gap by acting as an integrated Contract Research and Development Organization (CRO) and Contract Development and Manufacturing Organization (CDMO). We ensure that every pilot run directly translates to full-scale commercial manufacturing with comprehensive analytical method validation under ICH Q2(R1) guidelines.
The inherent bottleneck of plant-derived active substances lies in climatic and soil-dependent chemical composition fluctuations. Plants harvested from different provinces or seasons exhibit massive shifts in therapeutic secondary metabolites.
Our localized research facilities evaluate active ingredient yields across harvesting cycles, plant parts (leaves, rhizomes, seeds), and geological origins. By implementing Standardized Sourcing Indexes (SSI), we eliminate raw material variance before solvent extraction commences, protecting brand formulation integrity from multi-ton variability.
Regulatory scrutiny from the US FDA, European EFSA, and China's NMPA has reached historic highs. Health and functional claims require incontrovertible biological data demonstrating cellular uptake, target receptor binding, and absence of toxicity.
MedGence's in-house laboratory assets provide direct animal testing, cellular in vitro testing, LD50 toxicity evaluations, and human clinical trial protocols. This turnkey research structure drastically decreases client developmental cycle times from years to months.
Harnessing China’s geological biodiversity and manufacturing clusters to deliver unmatched raw-material sovereignty, scalable throughput, and cost stability.
China is home to over 11,000 medicinal plant taxa. MedGence leverages deep partnerships across geo-authentic (Daodi) agricultural regions, spanning the botanical clusters of Hunan, Yunnan, Sichuan, and Guizhou. By securing contracted Good Agricultural and Collection Practices (GACP) bases, we control cultivation protocols from non-GMO seed selection and chemical fertilizer ban policies to precision harvest dates.
This upstream integration shields global partners from market spot-price turbulence and protects raw material provenance against synthetic adulteration and botanical cross-contamination.
Our pilot plant and collaborative commercial facilities deploy advanced industrial bio-separation technologies. Traditional heat refluxing is replaced or augmented by:
A frequent pain point for Western R&D organizations is the "Valley of Death" between academic laboratory isolation and industrial CDMO scale-up. Process parameters refined in 5-liter glass flasks often fail when scaled to 5,000-liter stainless steel extractors.
Our engineering division manages both an agile 100L–500L pilot testing facility and commercial multiphasic production suites. We de-risk scale-up by systematically mapping temperature gradients, hydrodynamic flows, crystallization kinetics, and spray-drying retention indices.
| Evaluation Parameter | MedGence China Integrated CDMO | Traditional European / US Processors | Commodity Ingredient Traders |
|---|---|---|---|
| Direct Agricultural Traceability | Full GACP geo-cluster integration with digital batch lot tracking to origin farms. | Multiple intermediary brokers; localized farm contracts are rarely accessible. | Zero traceability; blended bulk lots sourced on open spot markets. |
| Preclinical In-House Validation | Turnkey in vitro cellular assays, animal safety pharmacology, and HPLC fingerprinting. | Subcontracted to external CROs at high pricing and multi-month delays. | Non-existent; reliance on generic Certificate of Analysis (CoA) datasheets. |
| Industrial Extraction Agility | Flexible multisolvent suites (Water, EtOH, SFE CO2, Enzymatic Digestion) up to 10,000 MT. | High energy and overhead cost structures; limited specialized processing suites. | No processing capabilities; dependent on contract facilities. |
| IP & Formulation Protection | Strict contract research protocol; NDA-bound exclusive client ownership. | Standard IP policies, often pursuing collaborative patent splits. | Risk of formula leaking to open trading channels. |
Our active substances and finished formulations are synthesized, audited, and certified to meet the world’s most stringent pharmacopeial safety standards.
Global regulatory bodies enforce trace contaminant ceilings that render subpar botanical extracts immediately unsellable. We conduct systematic testing on every production lot:
Adulteration of botanical products—whether intentional through cheap filler herbs or accidental through morphological similarity—is a major liability for global brand reputations.
MedGence pairs classical botanical macro- and microscopic identification with Genomic DNA Barcoding (ITS2, rbcL, matK markers). This dual physical and molecular verification guarantees that every batch is 100% true to genus and species, ensuring absolute compliance with US FSMA and European food safety frameworks.
For pharmaceutical-grade botanical APIs and medical foods, scientific data without regulatory packaging is ineffective. Our dedicated regulatory affairs department prepares audit-ready dossiers:
How artificial intelligence, biocatalysis, and green chemistry are redefining the economics and potency of natural active substances.
Traditional screening methods take years of random extraction. MedGence integrates in silico computational pharmacology, network biology, and molecular docking algorithms. By simulating compound-target interactions against human enzyme cascades, our researchers predict therapeutic bioactivity across hundreds of phytomolecules simultaneously.
This accelerates candidate hit-rates for novel pharmaceutical candidates, anti-aging cosmeceuticals, and metabolic-support nutraceuticals, drastically reducing client preclinical spend.
Many botanical compounds present low natural abundance or poor oral bioavailability. By applying food-grade enzyme biotransformation (such as beta-glucosidases and cellulases), we cleave glycosidic bonds from precursor saponins and polyphenols, yielding biologically active rare aglycones.
This biological enhancement generates active substances with 5x to 20x greater intestinal absorption and targeted physiological potencies compared to crude extract powders.
Sustainability is no longer a corporate buzzword—it is an enterprise procurement mandate. Our manufacturing ecosystem incorporates circular solvent recovery distillation cycles (>95% solvent recovery efficiency), anaerobic digestor treatment of spent herb cake, and zero-carbon solar-assisted drying systems.
Clients receive comprehensive Scope 1, 2, and 3 carbon reduction metrics to substantiate their corporate ESG and clean-label claims in North American and EU retail sectors.
From pharmaceutical-grade botanical APIs to shelf-stable beverage emulsions, our CDMO pipelines are tuned to specific delivery mechanisms.
Supplying registered hospital preparations, modernized TCM extract granules, and botanical drug APIs. Fully documented under pharmacopeial monographs with quantitative single-marker assays.
Microencapsulated, phytosome-bound, and liposomal delivery systems designed to overcome polyphenol degradation in stomach acid and dramatically enhance systemic bioavailability.
Standardized botanical active fractions for clinical skincare. Supported by keratinocyte and fibroblast in vitro assays for anti-inflammatory, collagen synthesis, and anti-melanogenesis pathways.
100% cold-water-soluble spray-dried powders, micro-emulsions, and specialized bitterness-masked botanical complexes suitable for ready-to-drink formulations, gummies, and sachets.
From initial compound screening to full-scale finished dosage delivery, we provide end-to-end technical execution.
Systematic screening of complex plant secondary metabolomes using mass spectrometry to discover target bioactives balancing yield and clinical potential.
Comparative chromatographic mapping across geographic origins and harvest seasons to determine optimal procurement parameters.
Developing robust, reproducible HPTLC, HPLC-UV/DAD, and GC assays along with chromatographic fingerprinting for raw materials and formulations.
Refining extraction solvents, temperature curves, macroporous resin elution, and spray-drying retention indices to maximize batch purity.
Resolving hygroscopicity, poor flowability, degradation, and taste profiles in finished oral formulations.
Documenting safety thresholds via acute oral toxicity (LD50), chronic 90-day repeat dose regimens, and Ames mutagenicity testing.
Targeted primary cell assays investigating inflammatory cytokine regulation (TNF-α, IL-6), antioxidant capacity, and receptor interactions.
Animal efficacy and safety pharmacology models providing validation data for dietary supplement dossiers and botanical IND filings.
GCP-audited human clinical research programs including PK/PD profiling, pilot consumer trials, and multi-center clinical trials.
Modernizing traditional multi-herb prescriptions to create synergistic natural formulations supported by modern chemometric data.
Commercial-scale extraction and isolation delivering pure botanical powders, standardized pastes, concentrated liquids, and volatile oils.
Full-scale manufacturing of oral liquids, hard-shell capsules, softgels, tablets, and effervescent granules in cGMP-certified suites.
Our contract R&D and supply teams work closely with China's largest listed pharmaceutical groups and national TCM teaching hospitals.
Detailed answers for technical sourcing directors, regulatory affairs executives, and procurement teams.
Accelerate your procurement pipeline with our specialized active ingredient screening, evaluation, and pilot-to-commercial scale services.
Isolating target botanical molecules from complex matrices to maximize bio-potency and sustainable extraction yields.
Quantifying phytochemical variance across regions and harvest cycles to optimize raw material procurement strategies.
Validating HPLC, HPTLC, and GC chromatographic methods to ensure regulatory compliance and batch consistency.
Executing GCP-compliant human studies for dietary supplements, health claims, and botanical drug registration dossiers.
Rapid cell-based and enzymatic assays evaluating pathway activation, bioavailability, and mechanistic safety profiles.
GLP-compliant animal models delivering toxicological profiles, pharmacokinetic data, and biological efficacy validation.
Pilot-to-commercial extraction delivering standardized liquids, fine powders, crystalline compounds, and volatile oils.
Turnkey CDMO production for oral liquids, capsules, softgels, tablets, and granules under strict cGMP protocols.
Connect directly with our pharmacognosy specialists, extraction engineers, and regulatory affairs team. Request technical dossiers, pilot scale testing, or standard extract specifications via [email protected].